Australian Biotech Viralytics Breaks Out With Doubling Deal
This article was originally published in PharmAsia News
Executive Summary
With one deal, Australia’s Viralytics doubles its market capitalization to $48 million from $24 million, which can bring its lead melanoma product through trials to commercialization.